AUDIENCE: Psychiatry, Cardiology
ISSUE: FDA notified healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Changes in the electrical activity of the heart (prolongation of the QT interval of the electrocardiogram [ECG]) can lead to an abnormal heart rhythm (including Torsade de Pointes), which can be fatal. Patients at particular risk for developing prolongation of the QT interval include those with underlying heart conditions and those who are predisposed to low levels of potassium and magnesium in the blood.
Studies did not show a benefit in the treatment of depression at doses higher than 40 mg per day. Previously, the citalopram drug label stated that certain patients may require a dose of 60 mg per day. The citalopram drug label has been revised to include the new drug dosage and usage recommendations, as well as information about the potential for QT interval prolongation and Torsade de Pointes. See the FDA Drug Safety Communication Data Summary for additional information.
BACKGROUND: Celexa (citalopram hydrobromide) is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs).
RECOMMENDATION: Citalopram causes dose-dependent QT interval prolongation. Citalopram should no longer be prescribed at doses greater than 40 mg per day. Citalopram should not be used in patients with congenital long QT syndrome. Patients with congestive heart failure, bradyarrhythmias, or predisposition to hypokalemia or hypomagnesemia because of concomitant illness or drugs, are at higher risk of developing Torsade de Pointes. See the FDA Drug Safety Communication for additional recommendations for healthcare professionals and patients.
Healthcare professionals and patients are encouraged ...more
LINKING POLICY AND DISCLAIMER
Healthesystems may link to other Web sites created and maintained by other public and/or private organizations. Healthesystems provides links to those Web sites as a service to our users. The presence of a link is not a Healthesystems endorsement of the Web site nor is it a guarantee that every similar link will be provided, e.g., not all FDA recalls will be provided as a link on this site.
When users follow a link to an outside Web site, they are leaving Healthesystems and are subject to the privacy and security policies of the owners/sponsors of the outside Web site(s). Healthesystems is not responsible for information collection practices on non-Healthesystems Web sites.
Changes to this Statement
Healthesystems will occasionally update this Privacy Statement to reflect company and customer feedback. Healthesystems encourages you to periodically review this Statement to be informed of how Healthesystems is protecting your information.
Contact Information
Healthesystems welcomes your comments regarding this Privacy Statement. If you believe that Healthesystems has not adhered to this Statement, please contact Healthesystems at communications@healthesystems.com. We will use commercially reasonable efforts to promptly determine and remedy the problem.